AstraZeneca To Delist From Nasdaq, Join NYSE In February

Reuters01-20

Jan 20 (Reuters) - AstraZeneca AZN.L on Tuesday said it would delist its American Depositary Shares and debt securities from Nasdaq and complete a direct listing of its ordinary shares and debt on the New York Stock Exchange, effective after market close on January 30, 2026.

The ordinary shares and debt securities are expected to commence trading on the NYSE from February 2, with AstraZeneca maintaining its "AZN" ticker symbol.

The move is part of a shareholder-approved plan to unify the company's share listing structure, allowing investors to trade its ordinary shares across the London Stock Exchange, Nasdaq Stockholm and the NYSE.

Following implementation of the harmonised structure, AstraZeneca will shift from trading ADSs - which represent ordinary shares on a two-for-one basis - to a direct listing of its $0.25 ordinary shares, simplifying its multi-market trading setup.

AstraZeneca fell 4% in premarket.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment